Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineering antibodies for therapy.

Leonard G Presta1

  • 1DNAX Research Institute, Palo Alto, CA 94304-1104, USA. leonard.presta@dnax.org

Current Pharmaceutical Biotechnology
|August 8, 2002
PubMed
Summary

This review highlights advances in antibody engineering for improved therapeutic efficacy. Innovations in antibody generation, screening, and functional enhancement are paving the way for next-generation antibody therapeutics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.

Nature communications·2023
Same author

TCR mimic compounds for pHLA targeting with high potency modalities in oncology.

Frontiers in oncology·2022
Same author

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Blood·2014
Same author

Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.

Journal of immunological methods·2010
Same author

Molecular engineering and design of therapeutic antibodies.

Current opinion in immunology·2008
Same author

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

International immunology·2006

Area of Science:

  • Biotechnology
  • Immunology
  • Drug Discovery

Background:

  • Therapeutic antibody research is rapidly expanding, with numerous antibodies approved and in clinical trials.
  • Significant progress has been made in antibody engineering to improve therapeutic potential.

Purpose of the Study:

  • To review recent advancements in antibody engineering for therapeutic applications.
  • To discuss methods for antibody generation, screening, and optimization of antibody fragments.

Main Methods:

  • Ex vivo antibody generation and screening systems.
  • Protein alteration and carbohydrate optimization for effector function modulation.
  • Engineering of antibody conjugates, multivalent, and multispecific antibodies.

Main Results:

  • Development of strategies for higher affinity, stability, and improved biodistribution of antibody fragments, particularly for solid tumors.
  • Methods to engineer effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement fixation (CDC), and to optimize antibody half-life.
  • Expansion of antibody utility through conjugates (immunotoxins, immunocytokines) and complex formats (multivalent, multispecific).

Conclusions:

  • Recent engineering approaches enable the generation of superior antibody therapeutics.
  • Novel strategies, including the IgA/FcalphaRI system, offer new avenues for therapeutic antibody development.

Related Experiment Videos